Drug Trial Radar · NCT05922124
Cefiderocol and Ampicillin-sulbactam vs. Colistin +/- Meropenem for Carbapenem Resistant A. Baumannii
Last checked: Nov 19, 2026Latest source record: Aug 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
734
Planned (sponsor's estimate)
Start
Sep 1, 2024
Primary completion
Jul 2026
Study completion Sep 2026
Sponsor
- Lead sponsor
- Rambam Health Care CampusAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Monaldi Hospital; Rutgers Robert Wood Johnson Medical School; Pisa University Hospital; Assaf-Harofeh Medical Center; Sheba Medical Center
- First posted
- Jun 28, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Patients with bloodstream infections, hospital acquired pneumonia or ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii (CRAB) treated with cefiderocol combined with ampicillin sulbactam will be compared to patients treated treated with colistin alone or colistin combined with meropenem.
Conditions
- Carbapenem Resistant Bacterial Infection
- Acinetobacter Bacteremia
- Acinetobacter Pneumonia
Interventions
CefiderocolDrug
Test drug regimen
Ampicillin-sulbactamDrug
Synergistic combination
ColistinDrug
Historical comparator
MeropenemDrug
Historical comparator synergistic combination
Primary outcomes
What the sponsor says the trial is designed to measure.
- All cause mortalityTime frame: 28 days
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Rambam Health Care Campus
Haifa, Israel · Recruiting
Sheba Tel HaShomer Medical Campus
Ramat Gan, Israel · Recruiting
Shamir Medical Center (Assaf Harofeh)
Tel Aviv, Israel · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.